Image source: The Motley Fool.
Biota Pharmaceuticals (NASDAQ: AVIR)
Q4 2020 Earnings Call
Mar 30, 2021 , 4:30 p.m. ET
Operator
For further details see:
Biota Pharmaceuticals (AVIR) Q4 2020 Earnings Call TranscriptImage source: The Motley Fool.
Biota Pharmaceuticals (NASDAQ: AVIR)
Q4 2020 Earnings Call
Mar 30, 2021 , 4:30 p.m. ET
Operator
For further details see:
Biota Pharmaceuticals (AVIR) Q4 2020 Earnings Call TranscriptMarket Wire News is a media platform, the information on this page was provided by Motley Fool via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...